Related references
Note: Only part of the references are listed.Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015
Philip R. Spradling et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2018)
Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance
Vincent Lo Re et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus
Fasiha Kanwal et al.
CLINICAL INFECTIOUS DISEASES (2016)
Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network
Z. M. Younossi et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation
Barbara S. Taylor et al.
PUBLIC HEALTH REPORTS (2016)
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients
Alexis P. Chidi et al.
VALUE IN HEALTH (2016)
Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study
Karen M. Clements et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
Mehdi Najafzadeh et al.
ANNALS OF INTERNAL MEDICINE (2015)
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs
Lauren A. Canary et al.
ANNALS OF INTERNAL MEDICINE (2015)
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Soumitri Barua et al.
ANNALS OF INTERNAL MEDICINE (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies
Fabien Zoulim et al.
GUT (2015)
High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers
Barbara J. Turner et al.
HEPATOLOGY (2015)
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
Andrew J. Leidner et al.
HEPATOLOGY (2015)
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs
Joshua M. Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in US veterans
R. Gidwani et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Albert Do et al.
PLOS ONE (2015)
Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010
Maxine M. Denniston et al.
ANNALS OF INTERNAL MEDICINE (2014)
Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006-2012
Anil G. Suryaprasad et al.
CLINICAL INFECTIOUS DISEASES (2014)
Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010
Rania A. Tohme et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2013)
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Homie Razavi et al.
HEPATOLOGY (2013)
Share Paper
